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Abstract
Background: Mitochondrial DNA copy number (mtDNA CN) exhibits interindividual and intercellular variation, but
few genome-wide association studies (GWAS) of directly assayed mtDNA CN exist.
We undertook a GWAS of qPCR-assayed mtDNA CN in the Avon Longitudinal Study of Parents and Children
(ALSPAC) and the UK Blood Service (UKBS) cohort. After validating and harmonising data, 5461 ALSPAC mothers
(16–43 years at mtDNA CN assay) and 1338 UKBS females (17–69 years) were included in a meta-analysis. Sensitivity
analyses restricted to females with white cell-extracted DNA and adjusted for estimated or assayed cell proportions.
Associations were also explored in ALSPAC children and UKBS males.
Results: A neutrophil-associated locus approached genome-wide significance (rs709591 [MED24], β (change in SD
units of mtDNA CN per allele) [SE] − 0.084 [0.016], p = 1.54e−07) in the main meta-analysis of adult females. This
association was concordant in magnitude and direction in UKBS males and ALSPAC neonates. SNPs in and around
ABHD8 were associated with mtDNA CN in ALSPAC neonates (rs10424198, β [SE] 0.262 [0.034], p = 1.40e−14), but
not other study groups. In a meta-analysis of unrelated individuals (N = 11,253), we replicated a published
association in TFAM (β [SE] 0.046 [0.017], p = 0.006), with an effect size much smaller than that observed in the
replication analysis of a previous in silico GWAS.
Conclusions: In a hypothesis-generating GWAS, we confirm an association between TFAM and mtDNA CN and
present putative loci requiring replication in much larger samples. We discuss the limitations of our work, in terms
of measurement error and cellular heterogeneity, and highlight the need for larger studies to better understand
nuclear genomic control of mtDNA copy number.
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Introduction
Mitochondria are the cellular organelles responsible for
producing adenosine triphosphate (ATP), a ubiquitous
substrate required for metabolism. ATP is the final prod-
uct of the series of redox reactions that are facilitated by
the complexes of the respiratory chain (RC), located on
the cristae, the folded inner membrane of mitochondria.
Mitochondria possess their own genome (mtDNA), an
extra-nuclear, double-stranded, circular DNA molecule
of ~ 16.6 kb that is inherited maternally. Thirteen sub-
units contributing to complexes of the RC are encoded
by mtDNA, and the entire mitochondrial genome is
present at variable copy number in the cell. The relative
copy number of mtDNA (mtDNA CN) may reflect dif-
fering energy requirements between cells: those from ac-
tive tissues (e.g. liver, muscle, neuron) are observed to
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have higher mtDNA CNs compared to endothelial cells,
which are comparatively quiescent [1–3].
Several nuclear genes are known to influence the regu-
lation of mtDNA CN, and these are reviewed in detail
elsewhere [1, 4–6]. These include POLG [4–12] and
POLG2 [4, 5, 12], the catalytic and accessory subunits of
DNA polymerase-gamma, the principal enzyme impli-
cated in mtDNA replication. Other regulators include
TFAM (mitochondrial transcription factor A) [4, 13–17],
which initiates mtDNA replication, along with other fac-
tors TFB1M and TFB2M [4, 8, 18]. Regulators of these
transcription factors include PGC-1α (peroxisome
proliferators-activated receptor gamma coactivator 1
alpha) [4, 5, 8] and two nuclear respiratory factors
(NRF-1, NRF-2) [4, 5, 8]. Moreover, maintenance of rep-
lication requires an adequate mitochondrial nucleotide
supply [19]: nucleotides may be imported from the cyto-
sol or salvaged by specific mitochondrial enzymes. De-
fective phosphorylation of deoxyribonucleosides by
kinases encoded by DGUOK (deoxyguanosine kinase)
and TK2 (thymidine kinase) leads to dysfunctional mito-
chondrial dNTP synthesis and key regulators of dNTP
synthesis in the cytosol include the helicase C10orf2
(alias TWINK) [4–10, 12], along with thymidine phos-
phorylase (TYMP) [4, 5, 9] and the target of the
p53-transcription factor, p53R2 (encoded by RRM2B) [4,
6, 7, 9, 12]. The role of succinyl CoA synthase deficiency
as a cause of mtDNA depletion is less well understood,
but mutations in the alpha and β subunits of succinyl
CoA synthase genes (SUCLA2, SUCGL1) [6, 7, 9, 10]
may be associated with mitochondrial nucleotide deple-
tion [6].
To our knowledge, few genome-wide scans of mtDNA
CN have been published, and those that exist are of rela-
tively small sample size [16, 20, 21] or use in silico prox-
ies for mtDNA CN without actual biological
measurements [17]. We had access to directly assayed
mtDNA CN in a diverse set of study groups and so per-
formed hypothesis-generating genome-wide association
studies (GWAS) in ~ 14,000 individual participants from
the Avon Longitudinal Study of Parents and Children
(ALSPAC) and the UK Blood Service (UKBS) cohort.
For our main analyses, the two most comparable study
groups of adult females were combined in a joint ana-
lysis (N = 6799, approximately 10 times larger than pre-
vious GWAS of directly assayed mtDNA CN) [20, 21],
with results from the other groups presented as oppor-
tunistic, secondary analyses. It is known that cellular
heterogeneity contributes to mtDNA CN: granulocytes
have relatively few mitochondria, whereas lymphocytes
are rich in mitochondria, and therefore in mtDNA [22].
Since we also had access to data on white cell propor-
tions, estimated from methylation data in ALSPAC, and
assayed directly in UKBS, we performed sensitivity
analyses that considered DNA source (whole blood/
white cells), and controlled for white cell proportions.
Finally, we extracted two SNPs that were robustly re-
lated to mtDNA CN in a recent GWAS of mtDNA CN
measured in silico [17], and compared our results to
those published associations.
Participants and methods
Cohort details
ALSPAC is a prospective cohort of mothers and their
children. Between 1991 and 1992, 14,541 women living
in the former county of Avon, UK, were recruited during
pregnancy, of whom 13,761 were enrolled into the study
(women were aged between 16 and 43 years at recruit-
ment when samples for mtDNA CN analyses were ob-
tained). Further details are available in the cohort profile
papers [23, 24], and the study website contains details of
all data that are available through a fully searchable data
dictionary: http://www.bristol.ac.uk/alspac/researchers/
our-data/. Ethical approval for the study was obtained
from the ALSPAC Ethics and Law Committee and the
Local Research Ethics Committees.
The UK Blood Service control group is part of the
Wellcome Trust Case Control Consortium 2. The UK
National Blood Service (UKBS) consists of 3091 unre-
lated, healthy individuals (aged 17–69 years when sam-
ples for mtDNA CN assay were obtained), recruited
between September 2005 and February 2006. Informed
consent was obtained from all participants in accordance
with protocols approved by the Peterborough & Fenland
Local Research Ethics Committee in September 2005.
DNA samples
Blood samples used for mtDNA CN assay were collected
from ALSPAC mothers during routine antenatal care.
Children included in this study had DNA sampled at ei-
ther birth (from cord blood, these individuals are here-
after referred to as ALSPAC ‘neonates’) or at a follow-up
research clinic assessment at mean age 7 (range 6–9
years, hereafter ALSPAC ‘6–9-year-olds’). Antenatal
DNA from mothers was extracted using a phenol-
chloroform method [25]. DNA from ALSPAC children
was extracted using a phenol-chloroform (ALSPAC neo-
nates) or salting-out method (ALSPAC 6–9-year-olds)
[25]. DNA sources used for the mtDNA CN assay varied
by age group: DNA from whole blood was used for
6–9-year-olds, ALSPAC mothers’ DNA was extracted
from whole blood or white cells, and ALSPAC neo-
nates had DNA extracted from white cells, as de-
scribed previously [25].
UKBS blood samples were separated by density centri-
fugation, and white blood cells were retained to perform
DNA extractions, as previously described, using a
guanidine-chloroform-based method [26, 27]. Thus, in
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UKBS, the DNA source was white blood cells for all par-
ticipants. Blood composition information for UKBS sam-
ples was provided by Willem Ouwehand at the
University of Cambridge as part of an on-going collabor-
ation with Patrick Chinnery. These details are also sum-
marised in Table 1.
Genotype data
ALSPAC
ALSPAC mothers were genotyped on the Illumina
Human660W-Quad array (Illumina, San Diego, CA,
USA) at the Centre Nationale du Génotypage (CNG).
ALSPAC children were genotyped with the Illumina
HumanHap550-Quad array, by the Wellcome Trust
Sanger Institute, Cambridge, UK, and the Laboratory
Corporation of America, Burlington, NC, USA, using
support from 23andMe. Genotypes were called using
Illumina GenomeStudio®. Quality control (QC) was per-
formed using PLINK v1.07 [28], phasing using ShapeIT
(v2.r644) [29], and imputation was to the Haplotype Ref-
erence Consortium (v1.0), performed using IMPUTE
(v3) (http://mathgen.stats.ox.ac.uk/impute/impute.html).
The genome build used was GRCh37. Further details of
genotype QC are given in Additional file 1.
GWAS were run separately in 5461 ALSPAC mothers,
3647 6–9-year-olds, and 2102 neonates (see Add-
itional file 1 for details of selection into the study). Re-
latedness within each group of participants (mothers,
neonates, and 6–9-year-olds) was assessed by
identical-by-descent (IBD) proportions from a genetic
relatedness matrix, calculated using the GCTA standard
algorithm [30], based on 1.1 million HapMap3
best-guess tag SNPs, present at a combined allele fre-
quency of > 0.01 and imputation quality > 0.8 in 17,842
individuals. Within each group (mothers, 6–9-year-olds,
and neonates), participants were unrelated (IBD > 0.125;
i.e. first-cousin level). A subset of children was related to
the 5461 ALSPAC mothers: there were 1611 mother/6–
9-year-old pairs related at IBD > 0.125 (1570 pairs IBD >
0.45) and 869 mother-neonate pairs related at IBD >
0.125 (839 IBD > 0.45). For some sensitivity analyses, a
GWAS of a subset of 2833 mothers, who are unrelated
to any 6–9-year-olds or neonates at IBD > 0.125, is used.
SNPs were filtered by MAF < 0.01 and imputation score
< 0.8 in all study groups [31], leaving 7,360,988;
7,410,776; and 7,361,275 SNPs in ALSPAC mothers, 6–
9-year-olds, and neonates, respectively.
UKBS
The UKBS cohort was genotyped using the Illumina 1.2
M Duo platform. Raw genotype data (called using Illu-
minus [32], http://www.sanger.ac.uk/science/tools/illu-
minus) were downloaded from the European Genotype
Archive (http://www.ebi.ac.uk/ega). QC was performed
using PLINK v1.90 [33], phasing and imputation using
EAGLE2 (v2.0.5) [34], and PBWT [35] (imputation was
to the Haplotype Reference Consortium (v1.0) per-
formed using the Sanger Imputation Server [https://
imputation.sanger.ac.uk/]). The genome build was
GRCh37. Further details are given in Additional file 1.
GWAS were run in 2671 UKBS individuals (1333
males, 1338 females). Individuals were unrelated at any
level of IBD. After filtering by MAF < 0.01 and imput-
ation quality > 0.8, 7,441,490 variants remained
(7,369,986 males only and 7,373,492 females only).
Assay of mtDNA CN
For mtDNA CN assay details in ALSPAC and UKBS, see
Additional file 1. Both cohorts had mtDNA CN assayed
by quantitative PCR. Both assays used B2M as the
single-gene reference, but mtDNA amplicons differed.
Raw data are plotted in Additional file 2: Figure S1.
Despite differences in raw mtDNA CNs between study
groups, validation analyses of the two adult cohorts sug-
gested relative mtDNA CNs were reliable.
Cross-validation of qPCR methodology between centres
was performed on 384 random samples (169 from
ALSPAC, 185 from UKBS). Samples were assayed by PG
and AG in Bristol and RB in Newcastle, using
cohort-specific protocols. There was moderate-to-good
agreement between z-scores of mtDNA CNs assayed in
ALSPAC by AG and PG (r[Spearman] = 0.68) and be-
tween those obtained from the two sets of exchanged
plates (ALSPAC r[Spearman] = 0.58 [analysts: AG/RB]
and UKBS r[Spearman] = 0.69 [analysts: PG/RB]) (Add-
itional file 2: Figure S2). However, panel B of Add-
itional file 2: Figure S2 suggests that there may have
been some non-linearity when comparing the two assays.
To control for absolute differences in mtDNA CNs,
z-scored phenotypes were used in GWAS (after
log-transformation to approximate normality). Z-scores
were computed separately for ALSPAC mothers, 6–
9-year-olds, neonates, and UKBS.
Statistical analysis
Genome-wide association study
GWAS were undertaken separately for ALSPAC
mothers, ALSPAC 6–9-year-olds, ALSPAC neonates,
UKBS females, and UKBS males. Additive models were
fitted, using dosage data for ALSPAC and best-guess
data for UKBS. The genome-wide significance threshold
was p = 5e−08 [36].
Main analyses We had access to several study groups
with relevant data. Since these groups were diverse in
nature and were of relatively small sample sizes (com-
pared to some complex trait GWAS), we did not con-
sider them as ‘discovery’ and ‘replication’ cohorts.
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Instead, after validating and harmonising data (see the
‘Assay of mtDNA CN’ section), we considered our main
analyses to be hypothesis-generating GWAS of the two
most comparable groups, i.e. all adult females (5461
ALSPAC mothers and 1338 UKBS females). This deci-
sion also took into account results from some prelimin-
ary analyses that suggested some possible differences
between UKBS females and males (see Additional file 2:
Figures S3 and S4), although we acknowledge that we
have insufficient power to detect sex differences that are
not potentially due to chance.
Thus, results from ALSPAC mothers and UKBS fe-
males were meta-analysed (‘Meta-analysis 1’), using
random-effects models in order to protect against pos-
sible heterogeneity in effects between cohorts. Since
ALSPAC mothers had DNA extracted from two sources,
a sensitivity meta-analysis (‘Meta-analysis 2’, N = 4743)
restricted the ALSPAC mothers to 3405 females with
white cell DNA extracted by a phenol-chloroform
method (i.e. the most comparable subgroup to UKBS fe-
males, all of whom had white cell DNA extracted by a
guanidine-chloroform based method [26, 27]). Hetero-
geneity was assessed using Cochran’s Q statistic [37] and
the I2 statistic [38]. Using the summary statistics from
Meta-analysis 1, we estimated the variance explained in
mtDNA CN using LD score regression [39].
Secondary analyses Results from GWAS of 3647
ALSPAC children [6–9 years], 2102 ALSPAC neonates,
and 1333 UKBS males are presented as secondary ana-
lyses. We applied the same p value threshold for
genome-wide significance and also specifically looked at
whether hits identified in these groups showed similar
directions and magnitudes of association in the
meta-analyses of adult females. However, we did not
consider these groups to be suitable replication samples
for the main analyses of adult females, given their small
sample sizes and sex and age differences.
Look-up of top loci from a recent large GWAS of in
silico mtDNA CN A recent large GWAS (using a dis-
covery sample of 10,560 Han Chinese females) identified
TFAM (mitochondrial transcription factor A) and CDK6
(Cyclin Dependent Kinase 6), as loci strongly associated
with mtDNA CN estimated in silico, from sequence data
[17]. The replication sample for that study included
1753 ALSPAC children within the UK10K consortium
[40]. There is overlap between that group and the 6–
9-year-olds studied in the current analysis [17]. Using all
available unrelated participants in the current study (i.e.
excluding mother-child duos, N = 11,253 total), we
meta-analysed the two lead SNPs at these loci and com-
pared our results to those of this previous GWAS [17].
Covariates
Covariates included age at mtDNA CN assay, sex, and
DNA concentration (ng/μL) [41] (ALSPAC only, mea-
sured by a PicoGreen® fluorescence-based method), and
principal components (2 in ALSPAC, 4 in UKBS), to ad-
just for population structure. The ALSPAC mothers’
analysis was adjusted for DNA source (white cells or
whole blood) (see Table 1).
For all analyses, effect sizes adjusted for cell propor-
tions are also presented, since cell lineages vary in their
average numbers of mitochondria [22]. In ALSPAC, cell
proportions have been estimated in the ‘Accessible Re-
source for Integrated Epigenomics’ (ARIES) subset [42],
using DNA methylation data from the Illumina Infinium
HumanMethylation450 BeadChip (450 K) array and the
Houseman method [43]. Five hundred forty-six mothers,
606 6–9-year-olds, and 82 neonates included in this
study had cell proportion data. Proportions were esti-
mated from methylation data derived from the same time
points as mtDNA CNs were assayed (antenatally for
mothers, at birth and ~ 7 years for children). In this study,
we only performed cell proportion-adjusted analyses if
participants had mtDNA CN assayed in the same DNA
sample type that was used for cellular proportion estima-
tion (i.e. white cells/whole blood) [44]. Lymphocytes (total
of CD8T, CD4T, B lymphocytes) and neutrophils (granu-
locytes for neonates [45]) were included as covariates for
mothers, with the addition of monocytes for 6–9-year-olds
and neonates (monocytes were not used in the mothers’
analyses since this prevented model convergence). In
UKBS, neutrophil and lymphocyte proportions derived
from full blood count data were included [27, 46].
Software
GWAS were performed with SNPTESTv2.5.0 [47] and
meta-analysed with META v1.7.0 [48]. The ‘qqman’ R
package [http://cran.r-project.org/web/packages/qqman/
] was used to create Manhattan/quantile-quantile (QQ)
plots. The ‘bedtools’ ‘clusterBed’ function [https://
github.com/arq5x/bedtools2] [49] was used to group
SNPs associated at p < 1e-06 (except for the 'Meta-Ana-
lysis 2', see footnote of Table 2) into 1Mb clusters, which
were then annotated with ANNOVAR [50] [http://anno-
var.openbioinformatics.org/en/latest/]. Regional associ-
ation plots were produced with LocusZoom v1.3, using
an hg19 reference (1000G March 2012) [51].
Power
An R implementation of the method used by Genetic
Power Calculator [52, 53] was used to determine the mini-
mum detectable effect sizes at 80% power, given the sam-
ple size of the study groups used in the main
meta-analyses (‘http://www.cureffi.org/2012/12/05/power-
for-gwas-and-extreme-phenotype-studies/’). This method
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requires ‘total QTL variance’ (i.e. the proportion of vari-
ance in a quantitative trait locus,Vq explained by the causal
variant) as input. Assuming a standardised normal distri-
bution (phenotype in SD units), the following is true:
Vq ¼ β2p
where β is the effect size (in SD units) and p is the
minor allele frequency (MAF). Estimated minimal ef-
fect sizes for our given sample sizes, a range of Vq
values was calculated, with a minimum value of 0.001
(equivalent to an effect size of 0.316 at MAF = 0.01
and 0.045 at MAF = 0.5). Linkage disequilibrium (LD)
of 0.8 (measured by the D’ metric) was assumed be-
tween causal and tag variants. Power curves are
shown in Additional file 2: Figure S5. Heat maps of
power by effect size and MAF are shown in Add-
itional file 2 Figure S6. For the largest (N = 6799
[5461 + 1338]) and smallest (N = 1333) GWAS under-
taken in this paper (i.e. the main meta-analysis of
adult females and the smallest secondary analysis of
UKBS males, respectively), minimum Vq values de-
tectable were 0.0091 and 0.0458. At MAF = 0.25, this
is equivalent to effect sizes of 0.191 and 0.428. How-
ever, it should be noted that these calculations do not
take account of measurement error in mtDNA CN,
white cell heterogeneity, covariate adjustment, or the
use of random-effects meta-analysis for the main
GWAS.
Results
Main analysis
Manhattan/QQ plots for GWAS of ALSPAC mothers (for
all 5461 mothers and for 3405 with white cell-extracted
DNA), UKBS females, and the two meta-analyses are
shown in Figs. 1 and 2. Values of lambda from genomic
control calculations are provided in the appropriate figure
legend. Regional association plots for loci identified from
the meta-analyses are in Fig. 3. For strongest associations
from separate GWAS of ALSPAC mothers and UKBS fe-
males, see Additional file 3: Tables S1, S2, S3, S4, and S5
and Additional file 1.
Results from the main meta-analysis of adult females
(N = 6799, ‘Meta-analysis 1’) as well as the analysis re-
stricted to those with white cell-extracted DNA (N =
4743, ‘Meta-analysis 2’) are given in Table 2. SNPs in as-
sociated regions were clustered into 1Mb windows [49].
For each analysis, results are shown before and after
cell-proportion adjustment. Annotations are given for
loci within 200 kb [54]. Coordinates are hg19.
Meta-analysis 1: all adult females (N = 6799)
No SNP passed the genome-wide significance threshold
of p < 5e−08. The top panel of Table 2 describes two top
loci (p < 1e−06) identified from the main meta-analysis
of all adult females: these included an intergenic locus
on chr13 (lead SNP rs12873707, β [SE] 0.159 [0.030], p
= 9.27e−08, I2 = 0) and a locus on chr17 (lead SNP
rs709591, β [SE] − 0.084 (0.016) p = 1.54e−07, I2 = 0). A
list of all SNPs associated at p < 1e−06 in these loci is
given in Additional file 3: Table S6. Using summary sta-
tistics for all SNPs included in this meta-analysis, we
used LD score regression to calculate the estimated total
observed scale heritability as 0.052 [SE = 0.079].
Regional association plots (see panels A and B of
Fig. 3) show the LD structure at these loci. Panel A
shows that there are no nearby SNPs in LD with the
lead chr13 variant. Panel B shows a large region of
LD at the chr17 locus, spanning the genes PSMD3,
CSF3, and MED24. SNPs in this region are associated
with neutrophil count [27]; given this fact, and since
cellular heterogeneity affects mtDNA CN [22, 55, 56],
this locus was assessed in more detail, by extracting
the SNP from all study groups (Table 3). Despite dif-
ferences in the proportion of participants with infor-
mation that enabled adjustment for cell type, there
was consistency across study groups with each show-
ing an approximate 50% attenuation of the effect size
with adjustment for cell proportions.
Meta-analysis 2: adult females with white cell-extracted
DNA (N = 4743)
The bottom panel of Table 2 gives details of the stron-
gest association in the meta-analysis restricted to
ALSPAC mothers with DNA extracted from white cells
(‘Meta-analysis 2’). The locus associated with mtDNA
CN (p < 1e−06) was rs150387260, an intergenic variant
(β [SE] 0.405 [0.084], p = 1.65e−06, I2 = 0, see also Add-
itional file 3: Table S7). A regional association plot
(panel C of Fig. 3) shows that few neighbouring SNPs
are in substantial LD with this SNP. The nearest gene
was RB1 Inducible Coiled-Coil 1 (RB1CC1), 78 kb up-
stream. The product of this tumour suppressor gene is
implicated in cell growth, migration, proliferation, apop-
tosis, and autophagy [57]. RB1CC1 deletions are associ-
ated with increased numbers of mitochondria in
haematopoietic stem cells [58] and mice [59] and with
breast cancer in humans [60].
Effect of adjusting for cell proportions in these two meta-
analyses
In Meta-analysis 1 (all adult females, regardless of DNA
source), point estimates attenuated after cell proportion
adjustment, although the reduced sample size meant
that confidence intervals were wide. In contrast, after
cell proportion adjustment for the association identified
from Meta-analysis 2 (restricted to females with white
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Fig. 1 a Manhattan (left)/quantile-quantile (QQ) plots (right) for ALSPAC (all mothers). λ = 0.995. ‘Minimally adjusted’ refers to the fact that these
results are from the analysis that did not adjust for cell proportions. b Manhattan (left)/quantile-quantile (QQ) plots (right) for UKBS (females). λ =
1.011. ‘Minimally adjusted’ refers to the fact that these results are from the analysis that did not adjust for cell proportions. c Manhattan (left)/
quantile-quantile (QQ) plots (right) for random-effects meta-analysis of ALSPAC (all mothers) and UKBS (females). λ = 0.995 and 1.011 for ALSPAC
(all mothers) and UKBS females, respectively, and meta-analyses are corrected for these lambdas. ‘Minimally adjusted’ refers to the fact that these
results are from the analysis that did not adjust for cell proportions
Fig. 2 a Manhattan (left)/quantile-quantile (QQ) plots (right) for ALSPAC (white cell mothers). λ = 0.992. ‘Minimally adjusted’ refers to the fact that
these results are from the analysis that did not adjust for cell proportions. b Manhattan (left)/quantile-quantile (QQ) plots (right) for random-
effects meta-analysis of ALSPAC (white cell mothers) and UKBS females. λ = 0.992 and 1.011 for ALSPAC (white cell mothers, see Fig. 2a) and UKBS
females (see Fig. 1b), and meta-analyses are corrected for these lambdas. ‘Minimally adjusted’ refers to the fact that these results are from the
analysis that did not adjust for cell proportions
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cell-extracted DNA), confidence intervals were also
wide, but the effect estimate was not attenuated (it in-
creased slightly).
Secondary analyses
Table 4 shows results of GWAS in ALSPAC 6–9-year-
olds, neonates, and UKBS males. Only genome-
wide-significant loci are shown (for UKBS males, top
loci at p < 1e−06 are shown, as there were no loci p < 5e
−08). When comparing effect sizes between any hits in
these groups with effects of the same SNPs in the
main (adult female) analyses, it should be noted that
there are ~ 1600 mother-child duos between ALSPAC
mothers included in the main analysis and the 6–
9-year-olds/neonates (see the ‘Methods’ section). Re-
sults of the associations of SNPs at a known neutro-
phil count locus (PSMD3, CSF3, MED24) identified in
our main analyses in these secondary analysis groups
are discussed above (see the ‘Main analysis’ section).
Associations in ALSPAC 6–9-year-olds
There were two genome-wide significant, intergenic loci
in 6–9-year-olds (rs139045492 on chr20, β [SE] − 0.695
[0.119], p = 6.35e−09 and rs144874692 on chr3, β [SE] −
0.632 [0.112] p = 1.78e−08). The rs139045492 associ-
ation persisted after cell proportion adjustment. The
SNP rs139045492 was not directionally concordantly (or
statistically significantly) associated with mtDNA CN in
either of the adult female main meta-analyses. The other
association (rs144874692), which attenuated after
cell-proportion adjustment, was not available in the
main analysis. Therefore, a proxy (rs144928561, r2 =
0.29, β [SE] − 0.328 [0.105], p = 0.002 in ALSPAC 6–
9-year-olds) was used to explore whether there was any
evidence of it being associated with mtDNA CN in the
main analyses. This proxy SNP was not directionally
concordantly associated in either main meta-analysis.
Manhattan/QQ plots are available in Additional file 2:
Figure S7. A list of all SNPs at p < 1e−06 in the 6–
9-year-olds is available in Additional file 3: Table S8.
(See figure on previous page.)
Fig. 3 Regional association plots (created with LocusZoom). These three regional association plots (a, b, and c, created with LocusZoom) detail
the top loci presented in the meta-analyses of all ALSPAC mothers and UKBS females (a, b) and of the one locus identified after restriction of the
meta-analysis to ALSPAC mothers with DNA extracted from white cells, only (c). In each plot, the lead SNP (i.e. the SNP with the lowest p value) is
annotated in purple, with other SNPs colour coded according to their values of linkage disequilibrium (in r2) with the lead SNP. Transformed,
−log10p values and recombination rate (in centimorgans per megabase, cM/Mb) are shown on the left and right y-axes, respectively. A schematic
of the genes in each region, along with coordinates and annotations, is shown at the bottom of each plot, with chromosomal location in
megabases (Mb) along the x-axis. See Table 2 for more details of each locus
Table 2 Summary statistics for top SNPs associated with mtDNA CN in two random-effects meta-analyses
Meta-analysis 1: ALSPAC mothers (N = 5461) and UKBS females (N = 1338)
rsID Cluster chr:pos_nonEA_EA β (SE)
P
Q
P (het)
I2 β (SE)
P (ALSP)
β (SE)
P
(UKBSF)
Location Lead SNP locus (or distance to
genes within 200 kb, in bp)
Genes in
this cluster
β (SE)
P (CC)a
rs12873707 13:104777684-
104810437
13:104810437_T_C 0.159
(0.030)
p
= 9.27E
−08
0.169
p
= 0.681
0 0.165
(0.033)
p
= 4.34E
−07
0.131
(0.076)
p
= 0.084
Intergenic . . 0.081
(0.060)
p
= 0.176
rs709591 17:38140926-
38179290
17:38175561_T_A − 0.084
(0.016)
p
= 1.54E
−07
0.092
p =
0.762
0 − 0.086
(0.018)
p
= 1.05E
−06
− 0.073
(0.038)
p
= 0.056
UTR3 MED24 CSF3,
MED24,
PSMD3
− 0.025
(0.033)
p
= 0.453
Meta-analysis 2: ALSPAC mothers (white cell samples only, N = 3405) and UKBS females (N = 1338)
rsID Cluster chr:pos_nonEA_EA β (SE)
P
Q
P (het)
I2 β (SE)
P (ALSP)
β (SE)
P
(UKBSF)
Location Lead SNP locus (or distance to
genes within 200 kb, in bp)
Genes in
this cluster
β (SE)
P (CC)a
rs150387260 8:53704895-
53704896
8:53704896_G_A 0.405
(0.084)
p
= 1.65e
−06
0.025
p
= 0.875
0 0.397
(0.098)
p
= 4.98e
−05
0.428
(0.169)
p
= 0.011
intergenic RB1CC1 (dist = 77,870), NPBWR1
(dist = 147,572)
. 0.720
(0.336)
p
= 0.032
The top panel shows hits p < 1e−06 from the meta-analysis of all ALSPAC mothers (N = 5461) and UKBS females (N = 1338): ‘Meta-analysis 1’. The lower panel
shows a meta-analysis restricted to females with DNA extracted from white cells (3405 ALSPAC mothers, 1338 UKBS females). In Meta-analysis 2, there were no
associations at p < 1e−06, so instead the next strongest association is shown
Abbreviations: rsID SNP identifier; chr:pos_nonEA_EA chromosome, position, non-effect allele, effect allele; β regression coefficient (additive model); SE standard
error; P p value; Q Cochran’s Q statistic; bp base pairs; P (het) p value for heterogeneity; I2 statistic for heterogeneity; P (ALSP) p value in ALSPAC analysis
contributing to meta-analysis (N = 5461 or N = 3405); P (UKBSF) p value in UKBS females analysis; P (CC) P (cell-proportion adjusted version of meta-analysis)
aNB large drop in number of ALSPAC mothers after cell-proportion adjustment (see Table 1)
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Associations in ALSPAC neonates
The locus most strongly associated with mtDNA CN in
the ALSPAC neonates was at chromosome 19, in
ABHD8 (abhydrolase-domain containing 8) (lead SNP:
rs10424198, β [SE] − 0.262 (0.034), p = 1.40e−14). Six-
teen SNPs were identified at genome-wide significance
within BABAM1, ANKLE1, ABHD8, and MRPL34.
Whilst the standard error for this SNP was large after
cell-composition adjustment, this latter analysis was in a
tiny sample (N = 82), and yet still the point estimate
remained broadly consistent (cell-proportion adjusted β
[SE] − 0.326 [0.193], p = 0.095). However, there was no
evidence of a concordant association in either
meta-analysis from the main analyses. Manhattan/QQ
plots are available in Additional file 2: Figure S8. A list
of SNPs associated with mtDNA CN at p < 1e−06 in ne-
onates is available in Additional file 3: Table S9.
Associations in UKBS (males)
No SNPs were associated at p < 5e−08 in UKBS males.
Two SNPs were associated at p < 1e−06: an intronic
SNP in MYT1L (Myelin Transcription Factor 1 Like, β
(SE) 0.401 (0.078), p = 2.94e−07) and two intergenic
SNPs 121 kb upstream of PDZRN3 (PDZ Domain Con-
taining Ring Finger 3, lead SNP β [SE] − 0.497 [0.099], p
= 5.84e−07). Whilst these SNPs survived cell proportion
adjustment, neither locus showed evidence of an associ-
ation concordant in terms of direction and magnitude in
either main meta-analysis. Manhattan and QQ plots for
this analysis are available in Additional file 2: Figure S3.
A list of SNPs at p < 1e−06 in UKBS males is available
in Additional file 3: Table S10.
Look-up of top loci from a recent large GWAS of in silico
mtDNA CN
The results of a look-up of two loci (rs11006126 and
rs445) that are strongly associated with mtDNA CN
measured in silico [17] are presented in Fig. 4. Estimates
for these SNPs were extracted from and meta-analysed
across all study groups (after removing ALSPAC
mother-offspring pairs; total N for these meta-analyses =
11,253, see also the ‘Genotype data’ section). The SNP
rs11006126 was associated with mtDNA CN across our
study groups (β [SE] 0.046 [0.017], p = 0.007), but the ef-
fect size was considerably (~ 1/7 of the size) smaller than
that observed in the discovery and replication cohorts of
the in silico GWAS. There was no evidence of replica-
tion of rs445 across our study groups (β [SE] 0.021
[0.022], p = 0.328) compared with discovery and replica-
tion result from the in silico GWAS.
Discussion
We conducted the largest ever GWAS of directly
assayed mtDNA CN, in two population-based cohorts.
Although diversity between our study groups prevented
us from conceptualising a traditional discovery and rep-
lication model, we considered our study as hypothesis
generating and meta-analysed the two most comparable
groups (ALSPAC mothers and UKBS females) as our
main analyses and other subgroups as opportunistic, sec-
ondary analyses.
There were no genome-wide significant hits in the
meta-analysis of adult females, but SNPs at a known
neutrophil (and other leucocytes [61]) count locus
(PSMD3, CSF3, MED24) [62] were associated with
Table 3 General concordance of association at rs709591, before adjustment for cell proportions
Cohort Group Subgroup P Info score (imputation quality) β SE N
Unadjusted
ALSPAC Mothers All 1.05E−06 0.998 − 0.086 0.018 5461
White cell samples 6.26E−04 0.998 − 0.081 0.024 3405
Childrenb All 0.524 0.998 − 0.015 0.024 3647
Neonatesb All 1.36E−04 0.998 − 0.119 0.031 2102
UKBS All Females 0.056 0.999 − 0.073 0.038 1338
Males 0.025 0.999 − 0.090 0.040 1333
Cell-proportion adjusted (see Table 1 for covariates)
ALSPACa Mothers All 0.829 0.997 0.012 0.057 546
White cell samples 0.774 0.999 0.024 0.085 301
Childrenb All 0.702 0.998 0.019 0.051 606
Neonatesb All 0.661 1.000 − 0.08 0.18 82
UKBS All Females 0.278 0.999 − 0.044 0.041 1138
Males 0.241 0.999 − 0.049 0.042 1122
aNB large drop in power for ALSPAC in cell proportion adjusted analyses (see Table 1)
bSome children in these analyses are related to ALSPAC mothers, however, in N = 2833 unrelated ALSPAC mothers, this association persisted (β [SE] − 0.120
[0.024], p = 4.01e−07)
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mtDNA CN at p ~ 2e−07. There is extended LD across
these genes (see Fig. 3); although CSF3 (alias granulocyte
colony-stimulating factor) may be the most likely bio-
logical candidate [63], a previous study in Japanese indi-
viduals reported that the neutrophil count associated
SNP was most associated with PSMD3 expression
[62]. It is established that cellular heterogeneity is re-
lated to mtDNA CN [22], and one of the strengths of
this study is that we were able to control for this.
This chr17 locus showed notable consistency of effect
sizes across several study groups (UKBS males, UKBS
females, ALSPAC neonates), corresponding to a ~
0.08 reduction in SD units of log mtDNA CN per
risk allele. However, there was notable (~ 50%) at-
tenuation with adjustment for white cell proportions.
Thus, a key finding of this study is the importance
of undertaking GWAS of directly assayed mtDNA
CN in sample sizes that are much larger and that
also have measures of white cell proportions. Ideally,
these studies should also be sufficiently large to en-
able exploration of any possible variation in nuclear
genetic control of mtDNA copy number variation by
sex and age.
Secondary analyses in ALSPAC children (6–9 years)
and ALSPAC neonates and UKBS males revealed three
genome-wide significant hits: two intergenic loci in
ALSPAC 6–9-year-olds and a region containing ABHD8
(abhydrolase-domain containing-8) in ALSPAC neo-
nates. None of the associations we observed at this locus
in ALSPAC neonates were at all evident in the main
meta-analysis of adult females. We only identified one
published association of SNPs within ABHD8 with a dis-
ease trait (breast cancer) in the literature [64], although
it is notable that this gene lies in head-to-head orienta-
tion with mitochondrial ribosomal protein L34,
MRPL34. Another mitochondrial ribosomal protein,
MRPL37, has previously been found to associate with
mtDNA CN, which [20] raises the possibility that the
BABAM1-ANKLE1-ABHD8-MRPL34 locus might be a
true signal, despite the lack of evidence of effect in our
main analyses. Mitochondrial ribosomal proteins are
encoded by nuclear DNA, synthesised on cytoplasmic
Table 4 Lead SNPs in secondary analyses
ALSPAC 6–9-year-olds (N = 3647)
rsID Cluster chr:pos_nonEA_EA β (SE)
P
β (SE)
P (proxy)
Location Nearby genes Lead SNP locus (or
distance to genes
within 200 kb, in bp)
β (SE)
P (CC)a
β (SE)
P (MA1)
β (SE)
P (MA2)
rs139045492 20:22836201-
22836202
20:22836202_G_A − 0.695
(0.119)
p = 6.35E
−09
– Intergenic . SSTR4 (dist =
179,855)
− 0.489
(0.240)
p = 0.042
0.080
(0.078)
p = 0.306
− 0.005
(0.097)
p = 0.956
rs144874692 3:175689046-
175689047
3:175689047_G_A − 0.632
(0.112)
p = 1.78E
−08
− 0.328
(0.105)
p = 0.002
Intergenic . NAALADL2
(dist = 165,619)
− 0.024
(0.263)
p = 0.926
Proxy:
0.00
(0.075)
p = 1.00
Proxy:
0.016
(0.094)
p = 0.861
ALSPAC neonates
(N = 2102)
rsID Cluster chr:pos_nonEA_EA β (SE)
P
β (SE)
P (Proxy)
Location Nearby genes Lead SNP locus
(or distance to
genes within
200 kb, in bp)
β (SE)
P (CC)a
β (SE)
P (MA1)
β (SE)
P (MA2)
rs10424198 19:17354824-
17461934
19:17409671_C_T − 0.262
(0.034)
p = 1.40E
−14
– Intronic ABHD8, ANKLE1, ANO8,
BABAM1, DDA1, GTPBP3,
MRPL34, NR2F6, PLVAP,
USHBP1
ABHD8 − 0.326
(0.193)
p = 0.095
− 0.010
(0.017)
p = 0.556
0.002
(0.022)
p = 0.911
UKBS (males) (N = 1333)
rsID Cluster chr:pos_nonEA_EA β (SE)
P
β (SE)
P (Proxy)
Location Nearby genes Lead SNP locus
(or distance to
genes within
200 kb, in bp)
β (SE)
P (CC)
β (SE)
P (MA1)
β (SE)
P (MA2)
rs11687359 2:1969703-
1969704
2:1969704_G_A 0.401
(0.078)
p = 2.94e
−07
– Intronic MYT1L MYT1L 0.362
(0.080)
p = 6.52e
−06
0.006
(0.032)
p = 0.845
0.043
(0.041)
p = 0.286
rs13070764 3:73309902-
73310337
3:73309903_G_A − 0.497
(0.099)
p = 5.84e
−07
– Intergenic . PPP4R2
(dist = 194,892),
PDZRN3
(dist = 121,678)
− 0.509
(0.100)
p = 4.15e
−07
0.100
(0.043)
p = 0.020
0.098
(0.060)
p = 0.101
Abbreviations: rsID SNP identifier; chr:pos_nonEA_EA chromosome, position, non-effect allele, effect allele; bp base pairs; β regression coefficient (additive model);
SE standard error; P p value; P (Proxy) p value (for a proxy SNP, rs144928561, r2 = 0.29); P (CC) p value (cell-proportion adjusted analysis); P (MA1) pvalue (‘Meta-
analysis 1’, 6799 adult females); p value (MA2) P (‘Meta-analysis 2’, 4743 females with DNA from white cells)
aNB large drop in power for ALSPAC mothers (see Table 1)
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ribosomes, then imported into mitochondria, where they
facilitate the translation of mitochondrial mRNA, in
conjunction with the two mitochondrially encoded
rRNAs [65]. Whilst there are no candidate disorders for
MRPL34, other diseases, such as Parkinson’s disease
(previously linked to reduced mtDNA CN [66]), are re-
lated to other mitochondrial ribosomal proteins [20, 65,
67]. This locus also included an additional neighbouring
gene, GTP Binding Protein 3 (Mitochondrial) (GTPBP3),
associated with mtDNA CN at p ~ 5e−07; rare mutations
in this gene are known to cause a Leigh syndrome-like
disorder [68]. However, it is clear that independent repli-
cation will be needed in order to confirm these associa-
tions, since our current results are in a small sample
from our secondary analyses only, and could be attribut-
able to ‘winner’s curse’ [69]. In addition, if such an asso-
ciation were to replicate in future GWAS, careful
fine-mapping would be needed in order to further refine
the signal and suggest putative causal genes out of those
found to be associated.
The identification of the cell-count associated locus
(lead SNP in MED24) could suggest that some loci, such
Fig. 4 Extraction and meta-analysis of two top loci from Cai et al. [17] from study groups in this GWAS. SNPs for two loci identified in a GWAS of
in silico estimated mtDNA CN were extracted from each of the study groups in this cohort (NB: a smaller subset of 2833 ALSPAC mothers were
used, since there were mother-child duos present between the original study group of 5461 and the two groups of ALSPAC children) total N =
11,253. Columns: SNP = rsID; gene = gene name; group = study group, beta = effect size; LCI/UCI = 95% confidence interval (lower, then upper
bound); P = p value; and I2 = I2 metric for heterogeneity. Meta-analyses were by random-effects and are shown as black diamonds. For reference,
the ALSPAC estimate from Cai et al. [17] is shown for each locus. This replication group included ALSPAC 6–9-year-olds (with mtDNA CN assayed
from sequence data). Betas had to be harmonised, as those in Cai et al. [17] were given as SD change in mtDNA CN per SD increase in genotype.
SD of genotype was estimated from allele frequencies provided for the cohort by Cai et al. [17] given as 0.342 for rs445 and 0.169 for rs11006126
(in the supplement of this paper). SDs were then calculated as √(2 × (1-MAF) × MAF) (evaluating to 0.53 and 0.67 for rs11006126 and rs445,
respectively). Betas and standard errors were then transformed from those given in Table 1 of Cai et al. to a ‘per risk allele’ scale, by multiplying
the given beta by (1/the estimated SD), i.e. rs11006126 = 0.179 × (1/0.53); rs445 = 0.110 × (1/0.67). CaiALSPAC = result from Cai et al. [17]. UKBSF/
UKBSM = females and males in UKBS cohort
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as this chr17 locus, may be related to mtDNA CN only
via their association with cell composition. It is note-
worthy that the meta-analysis in which this locus was
identified included ALSPAC mothers with DNA ex-
tracted from both white cells and whole blood: it is pos-
sible that combining individuals with DNA prepared
from multiple sources could lead to preferential detec-
tion of loci associated with mtDNA CN predominantly
via their association with cellular heterogeneity. When
results from participants with more similar DNA sources
are pooled, the power to detect loci associated with
mtDNA CN independently of cell proportions may in-
crease: we postulate that the BABAM1-ANK-
LE1-ABHD8-MRPL34 locus might be such a
‘cell-composition independent’ locus (although as noted
above, this needs further exploration). For loci in this
latter category, controlling for cell proportions may im-
prove the signal-to-noise ratio of observed associations,
and failure to control for cellular proportions may act
akin to measurement error. Future work should seek to
assert whether associations of known neutrophil loci
with mtDNA CN are entirely due to cell composition in
DNA samples or whether these loci are detected because
mtDNA CN is causally related to leucocyte count [70].
Ideally, such studies would use directly assayed neutro-
phil data, as opposed to estimates of cellular compos-
ition. In addition, it might be useful to control
associations for platelet count, since platelets are anucle-
ate, but mitochondria-rich [71, 72]. However, we ac-
knowledge that in adjusting for cellular composition, it
is possible that we could induce bias, if mtDNA CN
plays a causal role in determining cell counts. It is for
this reason that we chose to present models adjusted
and unadjusted for cellular composition in our work,
and we compare the results throughout.
Beyond the possibility of true underlying genetic het-
erogeneity between our cohorts, several other technical
factors may have limited their comparability. We believe
that population stratification is unlikely to be a problem,
as analyses controlled for principal components, and the
correlation of MAFs for tops hits was high (see Add-
itional file 2 Figure S9). Another technical difference be-
tween study groups is the DNA extraction method used.
DNA extraction method has a considerable effect on
mtDNA CN assay [73] and similar qPCR assays, includ-
ing that of telomere length [74]. However, it is difficult
to assess the extent to which DNA extraction method
may have affected the performance of the mtDNA CN
assay, since extraction method in ALSPAC was also re-
lated to age at DNA sampling, and it is possible that the
genetic regulation of mtDNA CN varies across the life
course.
When we combined all our study groups and looked
at whether two hits from a previous in silico GWAS
were replicated, we found some evidence for one (a SNP
in mitochondrial transcription factor A (TFAM)), but
not the other (CDK6) [17]. Notably, the previously re-
ported SNP for the CDK6 locus (rs445) has also been
shown to be associated with leucocyte counts [61].
TFAM is known as ‘a key activator of mitochondrial
transcription’ and is involved in ‘promoter recognition
by the mitochondrial RNA polymerase’ [16], yet despite
the comparable sample sizes between our (N = 11,253)
and the previous in silico (N = 10,442 discovery and N =
1753 replication) analyses, we observed a considerably
smaller effect size for the TFAM hit (~ 1/7 the size of
the replication effect from the previous study, despite
partial overlap in participants between the previously
published result and our sample). We postulate that this
might flag an important limitation in our work, namely
that of measurement error. If a substantial component
of our assayed mtDNA CNs includes non-differential
measurement error, we would expect to see attenuation
of effect sizes in our results. This is possible in qPCR as-
says; indeed, although we demonstrated correlations in
relative mtDNA CNs in a validation analysis, we saw
some suggestion of non-linearity. Whilst our attempted
replication of the previous in silico GWAS hit had 100%
power to detect effect sizes of 0.338 SD units (for a SNP
with a MAF of 0.169, i.e. the TFAM SNP), this power
calculation will be overoptimistic if our mtDNA CN as-
says are affected by measurement error. Therefore, we
might suggest that in silico measurement of mtDNA CN
may have advantages over the directly assayed method
in this instance.
Conclusion
In conclusion, we confirm an association of TFAM with
mtDNA CN, and after performing a range of
hypothesis-generating GWAS in diverse study groups,
we present several putative regulators of mtDNA CN
that will require further follow-up. However, we gener-
ally observed poor concordance across study groups.
Overall, our main conclusion is that here we find no
strong evidence to support our primary hypothesis of
common loci regulating mtDNA CN in the study groups
used here. We assess and discuss the possible implica-
tions of cellular heterogeneity on our results and present
the directly assayed mtDNA CN assay as another ex-
ample of a qPCR assay that may be subject to measure-
ment error. These findings should be considered as
possible power-limiting factors in GWAS studying the
genomic regulation of mtDNA CN. Nonetheless, we be-
lieve that to fully understand nuclear genomic control of
mtDNA CN variation, it is necessary to conduct GWAS
of directly assayed mtDNA CN. Thus, our work (the lar-
gest GWAS to date) makes an important contribution in
terms of future requirements to gain this knowledge,
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which is necessary for fuller understanding of the biol-
ogy and potential clinical impact of subtle variation in
mtDNA CN.
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